Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity...
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
About this item
Full title
Author / Creator
Deben, Christophe , Boullosa, Laurie Freire , Fortes, Felicia Rodrigues , De La Hoz, Edgar Cardenas , Le Compte, Maxim , Seghers, Sofie , Peeters, Marc , Vanlanduit, Steve , Lin, Abraham , Dijkstra, Krijn K. , Van Schil, Paul , Hendriks, Jeroen M. H. , Prenen, Hans , Roeyen, Geert , Lardon, Filip and Smits, Evelien
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in oncology offers a cost-effective and time-efficient approach to developing new cancer therapies. Our research focuses on evaluating AF's select...
Alternative Titles
Full title
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8c03f6975c524c59adae79b1d8c7f709
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8c03f6975c524c59adae79b1d8c7f709
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-024-03012-z
